{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:23:17Z","timestamp":1786980197266,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purposes<\/jats:title>\n                    <jats:p>Programmed death-ligand 1 (PD-L1) testing is performed mainly on biopsy specimens in patients with advanced lung cancer. It is questionable whether the small amount of tissue analysed in biopsies may represent the true PD-L1 expression of a tumour.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, PD-L1 expression on tumour cells derived from bronchoscopy brush cytology, endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA), endobronchial biopsy, transbronchial biopsy (TBB) and computed tomography (CT)-guided transthoracic biopsy was compared to the PD-L1 expression of the corresponding surgical resection in lung cancer patients with regard to neoadjuvant treatment in-between.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A quantitative comparison between the diagnostic biopsy of the primary tumour with corresponding resected surgical specimens in a total of 113 lung cancer patients (60% male, mean age 65\u2009\u00b1\u20099\u00a0years) revealed a statistically significant correlation of PD-L1 expression on tumour cells (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.58,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;\u20090.001), for patients without neoadjuvant treatment in-between and for patients who underwent neoadjuvant treatment (both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Using a cut-off value of\u2009\u2265\u200950% PD-L1 TPS for comparing the biopsy samples and resected specimens, the concordance rate was 78% with a Cohen\u2019s Kappa of 0.45.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A statistically significant concordance for PD-L1 expression on tumour cells between biopsies from primary lung tumour and resected specimen was found, but of uncertain clinical accuracy. The use of a cut-off value of\u2009\u2265\u200950% PD-L1 TPS resulted only in a moderate agreement. Therefore, the interpretation of the PD-L1 determined form biopsy specimens status should only be considered with caution for treatment decisionsQuery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-022-04080-4","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T06:22:36Z","timestamp":1655360556000},"page":"1747-1754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment"],"prefix":"10.1007","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4857-9854","authenticated-orcid":false,"given":"D.","family":"Gompelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Brugger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bernitzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mosleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Prosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Geleff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Blessing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tiefenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hoetzenecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Idzko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Hoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"issue":"2","key":"4080_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Ar\u00e9n Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"key":"4080_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.lungcan.2022.03.002","volume":"166","author":"R Butter","year":"2022","unstructured":"Butter R, Hondelink LM, van Elswijk L, Blaauwgeers JLG, Bloemena E, Britstra R, Bulkmans N, van Gulik AL, Monkhorst K, de Rooij MJ, Slavujevic-Letic I, Smit VTHBM, Speel EM, Thunnissen E, von der Th\u00fcsen JH, Timens W, van de Vijver MJ, Yick DCY, Zwinderman AH, Cohen D, \u2019t Hart NA, Radonic T (2022) The impact of a pathologist\u2019s personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer. Lung Cancer 166:143\u2013149. https:\/\/doi.org\/10.1016\/j.lungcan.2022.03.002","journal-title":"Lung Cancer"},{"issue":"34","key":"4080_CR3","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.2017.74.7642","volume":"35","author":"R B\u00fcttner","year":"2017","unstructured":"B\u00fcttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, L\u00f3pez-R\u00edos F, Penault-Llorca F, Viale G, Wotherspoon AC, Kerr KM, Tsao MS (2017) Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol 35(34):3867\u20133876. https:\/\/doi.org\/10.1200\/JCO.2017.74.7642","journal-title":"J Clin Oncol"},{"issue":"10030","key":"4080_CR4","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer,, POPLAR Study Group (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387(10030):1837\u20131846. https:\/\/doi.org\/10.1016\/S0140-6736(16)00587-0","journal-title":"Lancet"},{"issue":"22","key":"4080_CR5","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC, KEYNOTE-189 Investigators (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"4080_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","volume":"100","author":"S Gandini","year":"2016","unstructured":"Gandini S, Massi D, Mandal\u00e0 M (2016) PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: a systematic review and meta-analysis. Crit Rev Oncol Hematol 100:88\u201398. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.02.001","journal-title":"Crit Rev Oncol Hematol"},{"key":"4080_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.lungcan.2019.06.005","volume":"134","author":"A Haragan","year":"2019","unstructured":"Haragan A, Field JK, Davies MPA, Escriu C, Gruver A, Gosney JR (2019) Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response. Lung Cancer 134:79\u201384. https:\/\/doi.org\/10.1016\/j.lungcan.2019.06.005","journal-title":"Lung Cancer"},{"issue":"10027","key":"4080_CR8","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"issue":"12","key":"4080_CR9","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/cncy.21937","volume":"125","author":"JJ Heymann","year":"2017","unstructured":"Heymann JJ, Bulman WA, Swinarski D, Pagan CA, Crapanzano JP, Haghighi M, Fazlollahi L, Stoopler MB, Sonett JR, Sacher AG, Shu CA, Rizvi NA, Saqi A (2017) PD-L1 expression in non-small cell lung carcinoma: comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathol 125(12):896\u2013907. https:\/\/doi.org\/10.1002\/cncy.21937","journal-title":"Cancer Cytopathol"},{"issue":"7","key":"4080_CR10","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","volume":"383","author":"N Howlader","year":"2020","unstructured":"Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, Mariotto AB, Lowy DR, Feuer EJ (2020) The effect of advances in lung-cancer treatment on population mortality. N Engl J Med 383(7):640\u2013649. https:\/\/doi.org\/10.1056\/NEJMoa1916623","journal-title":"N Engl J Med"},{"issue":"1","key":"4080_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/annonc\/mdv489","volume":"27","author":"M Ilie","year":"2016","unstructured":"Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalv\u00e9e S, Washetine K, Mouroux J, V\u00e9nissac N, Poudenx M, Otto J, Sabourin JC, Marquette CH, Hofman V, Hofman P (2016) Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 27(1):147\u2013153. https:\/\/doi.org\/10.1093\/annonc\/mdv489","journal-title":"Ann Oncol"},{"issue":"1","key":"4080_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cllc.2021.08.009","volume":"23","author":"Y Jin","year":"2022","unstructured":"Jin Y, Xue Q, Shen X, Zheng Q, Chen H, Zhou X, Li Y (2022) PD-L1 expression and comprehensive molecular profiling predict survival in nonsmall cell lung cancer: a real-world study of a large Chinese cohort. Clin Lung Cancer 23(1):43\u201351. https:\/\/doi.org\/10.1016\/j.cllc.2021.08.009","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"4080_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.cllc.2015.03.008","volume":"16","author":"S Kitazono","year":"2015","unstructured":"Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Sasada S, Watanabe S, Asamura H, Tamura T, Ohe Y (2015) Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non\u2013small-cell lung cancer. Clin Lung Cancer 16(5):385\u2013390. https:\/\/doi.org\/10.1016\/j.cllc.2015.03.008","journal-title":"Clin Lung Cancer"},{"issue":"10","key":"4080_CR14","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.jtho.2017.07.015","volume":"12","author":"C Li","year":"2017","unstructured":"Li C, Huang C, Mok TS, Zhuang W, Xu H, Miao Q, Fan X, Zhu W, Huang Y, Lin X, Jiang K, Hu D, Chen X, Huang P, Lin G (2017) Comparison of 22C3 PD-L1 expression between surgically resected specimens and paired tissue microarrays in non-small cell lung cancer. J Thorac Oncol 12(10):1536\u20131543. https:\/\/doi.org\/10.1016\/j.jtho.2017.07.015","journal-title":"J Thorac Oncol"},{"issue":"1","key":"4080_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","volume":"2","author":"J McLaughlin","year":"2016","unstructured":"McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL (2016) Quantitative assessment of the heterogeneity of pd-l1 expression in non-small-cell lung cancer. JAMA Oncol 2(1):46\u201354","journal-title":"JAMA Oncol"},{"issue":"7","key":"4080_CR16","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00432-018-2642-4","volume":"144","author":"L Rojk\u00f3","year":"2018","unstructured":"Rojk\u00f3 L, Reiniger L, T\u00e9gl\u00e1si V, F\u00e1bi\u00e1n K, Pipek O, V\u00e1gv\u00f6lgyi A, Ag\u00f3cs L, Fillinger J, Kajd\u00e1csi Z, T\u00edm\u00e1r J, D\u00f6me B, Sz\u00e1ll\u00e1si Z, Moldvay J (2018) Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients. J Cancer Res Clin Oncol 144(7):1219\u20131226. https:\/\/doi.org\/10.1007\/s00432-018-2642-4","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"4080_CR17","doi-asserted-by":"publisher","first-page":"20090","DOI":"10.1038\/srep20090","volume":"29","author":"J Sheng","year":"2016","unstructured":"Sheng J, Fang W, Yu J, Chen N, Zhan J, Ma Y, Yang Y, Huang Y, Zhao H, Zhang L (2016) Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep 29(6):20090. https:\/\/doi.org\/10.1038\/srep20090","journal-title":"Sci Rep"},{"issue":"1","key":"4080_CR18","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1186\/s12885-019-5773-3","volume":"19","author":"A Tsunoda","year":"2019","unstructured":"Tsunoda A, Morikawa K, Inoue T, Miyazawa T, Hosshikawa M, Takagi M, Mineshita M (2019) A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer. BMC Cancer 19(1):546. https:\/\/doi.org\/10.1186\/s12885-019-5773-3","journal-title":"BMC Cancer"},{"issue":"Suppl 1","key":"4080_CR19","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","volume":"24","author":"L Xia","year":"2019","unstructured":"Xia L, Liu Y, Wang Y (2019) PD-1\/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist 24(Suppl 1):S31\u2013S41. https:\/\/doi.org\/10.1634\/theoncologist.2019-IO-S1-s05","journal-title":"Oncologist"},{"issue":"12","key":"4080_CR20","doi-asserted-by":"publisher","first-page":"11541","DOI":"10.2147\/OTT.S223643","volume":"30","author":"H Xu","year":"2019","unstructured":"Xu H, Chen X, Lin D, Zhang J, Li C, Zhang D, Zhang X (2019) Conformance assessment of PD-L1 expression between primary tumour and nodal metastases in non-small-cell lung cancer. Onco Targets Ther 30(12):11541\u201311547. https:\/\/doi.org\/10.2147\/OTT.S223643","journal-title":"Onco Targets Ther"},{"issue":"10","key":"4080_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.551367","volume":"23","author":"L Zhao","year":"2021","unstructured":"Zhao L, Chen P, Fu K, Li J, Dai Y, Wang Y, Zhuang Y, Sun L, Chen H, Lin Q (2021) Concordance of PD-L1 status between image-guided percutaneous biopsies and matched surgical specimen in non-small cell lung cancer. Front Oncol 23(10):551367. https:\/\/doi.org\/10.3389\/fonc.2020.551367","journal-title":"Front Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04080-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04080-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04080-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T12:07:57Z","timestamp":1681301277000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04080-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["4080"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04080-4","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"assertion":[{"value":"9 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Medical University of Vienna (EK Nr: 1071\/2021) on 10<sup>th<\/sup> March 2021.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This retrospective study was conducted retrospectively from data obtained for clinical purposes. Informed consent for this retrospective study was not required as the research involves no more than minimal risk to the subjects.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This publication does not contain any individual person\u2019s data in any form.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}